MS and Demyelinating Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 11, 2022.

Dr Schmierer introduces the disease-modifying therapies (DMT) that are available for patients with MS and their impact on the immune system.

Klaus Schmierer, MB BS, PhD, FRCP, defines the pathophysiology of multiple sclerosis (MS).

The assistant professor of neurology at the University of Pennsylvania discussed how 7T MRI features of newly developed MS lesions can predict the development of chronic active lesions. [WATCH TIME: 3 minutes]

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research offered her insight into improving the recognition of autoimmune encephalitis. [WATCH TIME: 2 minutes]

Bruce Bebo, PhD, outlined findings from a recent analysis presented at ACTRIMS Forum 2022, with investigators concluding costs associated with the disease have previously been underestimated.

The William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, and Neurologist-in-Chief at Yale-New Haven Hospital spoke to the findings of a recent assessment of T cells in multiple sclerosis. [WATCH TIME: 4 minutes]

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.

Data provide an update to the post-approval safety profile of cladribine tablets in patients with relapsing MS in reference to COVID-19 infections.

Leigh Charvet, PhD, professor of neurology, NYU Grossman School of Medicine, discussed the potential feasibility of at-home tDCS for patients with multiple sclerosis to boost cognitive training. [WATCH TIME: 2 minutes]

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed the lack of guidelines for patients with RIS and the research efforts needed going forward to establish them.

Previously reported data show patients with multiple sclerosis treated with anti-CD20s have reduced response to COVID-19 vaccines, but there has been limited research on MS outcomes among vaccinated patients.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed her presentation at ACTRIMS Forum 2022 involving imaging biomarkers of RIS/MS prodrome. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is nutrition in multiple sclerosis.

A third dose enhanced the number of responders to all variants and significantly increased CD8 T-cell responses, but the frequencies of Omicron-specific CD8 T-cells remained 70% of the responses specific to the vaccine strain.

Neurology News Network for the week ending March 4, 2022. [WATCH TIME: 4 minutes]

Results from the preliminary study investigating the safety of the ketogenic diet for patients with MS were announced ahead of the AAN Annual Meeting in April 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 4, 2022.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research discussed the results of a new study on age and sex as determinants of autoimmune encephalitis. [WATCH TIME: 3 minutes]

Nine of 15 tested patients in the intrathecal stem cell group had a reduction of more than 50% in neurofilament light levels, compared with only 1 of 15 in the placebo group.

Investigators noted the need for more transformational treatments to improve disability for patients with both primary and secondary progressive multiple sclerosis.

Data suggest that there is a greater cognitive benefit for patients with higher levels of baseline neurological disability treated with the training and transcranial direct current stimulation.

The professor of neurology at the NYU Grossman School of Medicine discussed her presentation at ACTRIMS Forum 2022, which showed better cognitive outcomes in MS following treatment with tDCS. [WATCH TIME: 3 minutes]

The assistant professor of neurology at the University of Pennsylvania provided insight on a new way to accurately predict chronic active lesion evolution from newly developing MS lesions using 7T MRI.

The study found that all COVID-19 cases were mild to moderate in severity, and all enrolled patients recovered and remained in the study.

Investigators utilized a novel method to accurately capture spinal cord area at C1 vertebral level from legacy brain MRI scans.

The executive vice president of the National MS Society spoke on recently published data suggesting the relationship between EBV and MS, also sharing his opinion on the potential of vaccines. [WATCH TIME: 2 minutes]

Most trials that reported on MS-related fatigue measured its change from baseline and whether that change was statistically significant.